Saanroo announced the publication of a peer-reviewed clinical study showing that Levagen+ PEA (palmitoylethanolamide) significantly improved functional measures of joint health in dogs and cats. The six-week, randomized, double-blind, placebo-controlled trial on 50 dogs and 50 cats was the first study of its kind to evaluate Levagen+ in companion animals. The findings were published in Frontiers in Veterinary Science.

The study represented a logical next step for research on Levagen+, Saanroo reported, as it already has strong clinical backing in humans for joint health, recovery, and inflammatory modulation. Aging pets have a high prevalence of joint comfort and mobility issues, making it a clear opportunity for investigation.

In the study, 76% of dogs receiving Levagen were classified as successfully treated, compared to 40% of those that took a placebo; significant improvements were observed in multiple pain and functional interference domains.

In cats, statistically significant between-group differences were observed in specific functional tasks, like jumping up and jumping down. Reductions in scores on “pain today” evaluations were also significant by week 2, and through to week 6.

The supplement was well-tolerated in both species.

“Joint health is a common and growing concern for pet owners around the world, and because Levagen+ already had strong clinical backing in human joint health, it was only natural to explore whether it could deliver similar benefits in dogs and cats,” said John Quilter, CEO of Saanroo. “This first published companion animal study of Levagen + is an important milestone for the brand. It shows that the science behind Levagen + has relevance beyond human health and opens the door to new opportunities in companion animal wellness.”

In the paper’s discussion, the authors noted that current management of osteoarthritis and joint pain in animals is limited by adverse effects associated with the long-term use of pharmaceutical options, underscoring the need for well-tolerated alternatives that support mobility and daily function.

Levagen + is a unique form of PEA that is highly bioavailable; it utilizes Pharmako Biotechnologies’ LipiSperse to enhance dispersibility and absorption. It has been shown in clinical studies to support joint health, recovery, sleep, cognitive support, women’s health, stress, and companion animal health.